Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

Sagittarius Life Science Corp (3205.TWO)

Compare
22.05
-1.50
(-6.37%)
At close: April 11 at 1:30:38 PM GMT+8
Loading Chart for 3205.TWO
  • Previous Close 23.55
  • Open 22.05
  • Bid 22.00 x --
  • Ask 22.30 x --
  • Day's Range 21.30 - 22.35
  • 52 Week Range 21.30 - 51.70
  • Volume 240,346
  • Avg. Volume 94,742
  • Market Cap (intraday) 717.639M
  • Beta (5Y Monthly) 0.50
  • PE Ratio (TTM) --
  • EPS (TTM) -1.49
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Aug 31, 2018
  • 1y Target Est --

Sagittarius Life Science Corp engages in the research, development, and sale of Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.

www.naturalbiokey.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 3205.TWO

View More

Performance Overview: 3205.TWO

Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

3205.TWO
30.99%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
15.22%

1-Year Return

3205.TWO
48.42%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
5.90%

3-Year Return

3205.TWO
1.56%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
14.55%

5-Year Return

3205.TWO
34.08%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
92.26%

Compare To: 3205.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 3205.TWO

View More

Valuation Measures

Annual
As of 4/11/2025
  • Market Cap

    717.64M

  • Enterprise Value

    567.50M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.54

  • Price/Book (mrq)

    1.76

  • Enterprise Value/Revenue

    1.21

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -10.37%

  • Return on Assets (ttm)

    -6.50%

  • Return on Equity (ttm)

    -10.50%

  • Revenue (ttm)

    467.75M

  • Net Income Avi to Common (ttm)

    -48.53M

  • Diluted EPS (ttm)

    -1.49

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    160.9M

  • Total Debt/Equity (mrq)

    2.57%

  • Levered Free Cash Flow (ttm)

    -34.73M

Research Analysis: 3205.TWO

View More

Company Insights: 3205.TWO

Research Reports: 3205.TWO

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.